| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lung Neoplasms | D008175 | 171 associated lipids |
| Wounds and Injuries | D014947 | 20 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Diabetic Nephropathies | D003928 | 39 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gómez-Vaquero C et al. | Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. | 2016 | PLoS ONE | pmid:27911913 |
| Titanji K et al. | Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. | 2014 | PLoS Pathog. | pmid:25393853 |
| Lis GJ et al. | Influence of osteoclasts and osteoprotegerin on the mode of calcific degeneration of aortic valves. | 2016 | Pol. Arch. Med. Wewn. | pmid:27003233 |
| Janda K et al. | Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. | 2013 | Pol. Arch. Med. Wewn. | pmid:23535831 |
| Nehring P et al. | Osteoprotegerin gene rs2073617 and rs3134069 polymorphisms in type 2 diabetes patients and sex‑specific rs2073618 polymorphism as a risk factor for diabetic foot. | 2013 | Pol. Arch. Med. Wewn. | pmid:23299915 |
| Jasiewicz M et al. | Potential pathogenic role of soluble receptor activator of nuclear factor-ĸB ligand and osteoprotegerin in patients with pulmonary arterial hypertension. | 2014 | Pol. Arch. Med. Wewn. | pmid:25188298 |
| Stajszczyk M | [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. | 2002 | Pol. Arch. Med. Wewn. | pmid:12600190 |
| Adamczyk T et al. | Biomarkers of calcification and atherosclerosis in patients with degenerative aortic stenosis in relation to concomitant coronary artery disease. | 2012 | Pol. Arch. Med. Wewn. | pmid:22237719 |
| Ambroszkiewicz J et al. | [Concentration of osteoprotegerin, bone formation and resorption markers in patients with phenylketonuria]. | 2008 | Pol. Merkur. Lekarski | pmid:18839616 |
| Kmieć Z and Sokołowska I | [Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis--new therapeutical opportunities]. | 2007 | Pol. Merkur. Lekarski | pmid:17684931 |
| Hen K et al. | [Osteoprotegerin--a new atherosclerosis marker]. | 2011 | Pol. Merkur. Lekarski | pmid:22097184 |
| Ostrowska Z et al. | Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women. | 2011 | Postepy Hig Med Dosw (Online) | pmid:22100799 |
| Ostrowska Z | [Menopause, obesity, and bone status]. | 2009 | Postepy Hig Med Dosw (Online) | pmid:19252463 |
| Ostrowska Z et al. | Assessment of the relationship between melatonin, hormones of the pituitary-ovarian, -thyroid and -adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa. | 2013 | Postepy Hig Med Dosw (Online) | pmid:23752595 |
| Zdzisińska B and Kandefer-Szerszeń M | [The role of RANK/RANKL and OPG in multiple myeloma]. | 2006 | Postepy Hig Med Dosw (Online) | pmid:17013366 |
| Majerczyk M et al. | [Osteoprotegerin as a marker of atherosclerosis and a prognostic factor in stroke]. | 2015 | Postepy Hig Med Dosw (Online) | pmid:27259222 |
| Stanisławowski M and Kmieć Z | [The participation of RANK, RANKL and OPG in tumor osteolysis]. | 2009 | Postepy Hig Med Dosw (Online) | pmid:19502684 |
| Ostrowska Z et al. | Â Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa. | 2012 | Postepy Hig Med Dosw (Online) | pmid:23001207 |
| Wang Y et al. | Chicken receptor activator of nuclear factor-kappaB ligand induces formation of chicken osteoclasts from bone marrow cells and also directly activates mature osteoclasts. | 2008 | Poult. Sci. | pmid:18931186 |
| Jiang S et al. | Changes of blood parameters associated with bone remodeling following experimentally induced fatty liver disorder in laying hens. | 2013 | Poult. Sci. | pmid:23687138 |
| Fu YX et al. | Influence of osteoprotegerin on differentiation, activation, and apoptosis of Gaoyou duck embryo osteoclasts in vitro. | 2013 | Poult. Sci. | pmid:23687158 |
| Ta HM et al. | Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. | 2010 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21059944 |
| Yasuda H et al. | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. | 1998 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9520411 |
| Hsu H et al. | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:10097072 |
| Shimamura M et al. | OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:24847069 |
| Xiong L et al. | Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. | 2015 | Proc. Natl. Acad. Sci. U.S.A. | pmid:25733894 |
| Duheron V et al. | Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21402940 |
| Chen W et al. | Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:24733914 |
| Wei W et al. | Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. | 2012 | Proc. Natl. Acad. Sci. U.S.A. | pmid:22315431 |
| Krause U et al. | Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. | 2010 | Proc. Natl. Acad. Sci. U.S.A. | pmid:20150512 |
| Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |
| Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
| Toraldo G et al. | IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. | 2003 | Proc. Natl. Acad. Sci. U.S.A. | pmid:12490655 |
| Li JY et al. | Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21187391 |
| Baud'huin M et al. | A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. | 2012 | Proc. Natl. Acad. Sci. U.S.A. | pmid:22761317 |
| Cozzani M et al. | Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. | 2005 | Prog Orthod | pmid:16276433 |
| Malik P et al. | Bone mineral density and bone metabolism in patients with major depressive disorder without somatic comorbidities. | 2013 | Prog. Neuropsychopharmacol. Biol. Psychiatry | pmid:23380173 |
| Kuroyanagi G et al. | Suppression by resveratrol of prostaglandin D2-stimulated osteoprotegerin synthesis in osteoblasts. | 2014 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:24813642 |
| Fujita D et al. | Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. | 2003 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:12711253 |
| Poulsen RC et al. | Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. | 2008 | Prostaglandins Other Lipid Mediat. | pmid:18077200 |
| Li X et al. | Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. | 2002 | Prostaglandins Other Lipid Mediat. | pmid:12013525 |
| Kuroyanagi G et al. | (-)-Epigallocatechin gallate synergistically potentiates prostaglandin E2-stimulated osteoprotegerin synthesis in osteoblasts. | 2017 | Prostaglandins Other Lipid Mediat. | pmid:28163121 |
| Blackwell KA et al. | Bone morphogenetic protein 2 enhances PGE(2)-stimulated osteoclast formation in murine bone marrow cultures. | 2009 | Prostaglandins Other Lipid Mediat. | pmid:19744575 |
| Wiercinska-Drapalo A et al. | Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. | 2005 | Prostaglandins Other Lipid Mediat. | pmid:16303613 |
| Yamamoto N et al. | Resveratrol reduces prostaglandin E1-stimulated osteoprotegerin synthesis in osteoblasts: suppression of stress-activated protein kinase/c-Jun N-terminal kinase. | Prostaglandins Other Lipid Mediat. | pmid:25677506 | |
| Armstrong AP et al. | RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. | 2008 | Prostate | pmid:18008334 |
| Hesry V et al. | Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. | 2006 | Prostate | pmid:16541419 |
| Zheng Y et al. | Vitamin D deficiency promotes prostate cancer growth in bone. | 2011 | Prostate | pmid:21541977 |
| Yonou H et al. | Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. | 2007 | Prostate | pmid:17394194 |
| Eaton CL et al. | Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. | 2004 | Prostate | pmid:15042606 |